Navigation Links
ArunA Biomedical Announces Commercial Release of its Human Embryonic Stem Cell Derived Neural Cells
Date:1/30/2009

ATHENS, Ga., Jan. 30 /PRNewswire/ -- ArunA Biomedical, Inc., announced today that it will make its hN2(TM) cells commercially available to the research community in early 2009. The cells, derived from NIH registered human embryonic cell lines, are offered as a normal, consistent population of neural cells in an adherent monolayer format, a product never before offered to the research community. hN2 cells provide a human cell based format for research ranging from Alzheimer's to spinal cord injury and depression.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080819/CLTU003LOGO )

"ArunA has further developed its adherent monolayer technology by creating hN2(TM), a normal human neural cell ideal for drug screening, toxicology studies and basic neural research and we are pleased to be able to offer these cells commercially to the research market," says David Ray, ArunA's Chief Executive Officer. "By offering our products through multi-national distribution partners, we will provide broad access to the unique tools that may accelerate the pace of neural research with more physiologically relevant cellular research models," Ray said.

About ArunA Biomedical

Located in Athens, Georgia, ArunA Biomedical, Inc. is a privately held biotechnology corporation dedicated to the discovery, manufacturing and commercialization of emerging new technologies in human embryonic stem cell research for use in drug discovery and basic research. ArunA is the first company to commercialize products derived from human embryonic stem cells and sees its proprietary technology as a catalyst leading to the discovery of novel therapeutic compounds, tests for neurotoxicity and breakthroughs in understanding human development and diseases. The company's first product, hNP1(TM) (ENSTem-A(TM)), is based on patented technology licensed from the University of Georgia. For more information, visit www.arunabiomedical.com.


'/>"/>
SOURCE ArunA Biomedical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. ArunA Biomedical Names William T. Sharp President and Chief Executive Officer
2. ArunA Biomedical Announces Exclusive Worldwide Technology Licensing Agreement to Commercialize Human Embryonic Stem Cell Derived Mesenchymal Cells
3. Serica Technologies Expands Facilities in Massachusetts, Combines State-Of-The-Art Textile Engineering and Biomedical Manufacturing
4. CryoLife Signs Distribution Agreement for Inclusion of BioGlue(R) Surgical Adhesive in Hernia Repair Kit with Proxy Biomedical Surgical Meshes
5. Verax Biomedical Receives 510 (k) Clearance from FDA for Platelet PGD Test
6. SLIM Search, Inc. Sponsors Next Generation Sequencing Conference for the Biomedical Market
7. NCIIA Announces Launch of 4th Annual Student Biomedical Innovation Competition
8. New Scientists Boost Disease-based Research at Boston Biomedical Research Institute
9. Foundation for Biomedical Research Board Chairman Awarded Congressional Gold Medal
10. Crux Biomedical Announces First Successful U.S. Implant of Its New Retrievable Inferior Vena Cava (IVC) Filter
11. Environmental Tectonics Corporations BioMedical Division Announces New Contract
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... TOKYO , June 24, 2016  Regular discussions on ... to take place between the two entities said Poloz. ... in Ottawa , he pointed to the ... and the federal government. ... Poloz said, "Both institutions have common economic goals, why not ...
(Date:6/24/2016)... ... ... While the majority of commercial spectrophotometers and fluorometers use the z-dimension of 8.5 ... end machines that use the more unconventional z-dimension of 20mm. Z-dimension or ... the cuvette holder. , FireflySci has developed several Agilent flow cell product lines ...
(Date:6/23/2016)... Seattle, WA (PRWEB) , ... June 23, 2016 ... ... technology, announces the release of its second eBook, “Clinical Trials Patient Recruitment and ... patient recruitment and retention in this eBook by providing practical tips, tools, and ...
(Date:6/23/2016)... June 23, 2016   Boston Biomedical , ... compounds designed to target cancer stemness pathways, announced ... granted Orphan Drug Designation from the U.S. Food ... gastric cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin ... to inhibit cancer stemness pathways by targeting STAT3, ...
Breaking Biology Technology:
(Date:5/9/2016)... 2016 Elevay is currently known ... freedom for high net worth professionals seeking travel for ... connected world, there is still no substitute for a ... sealing your deal with a firm handshake. This is ... advantage of citizenship via investment programs like those offered ...
(Date:4/26/2016)... 2016 Research and Markets has ... Market 2016-2020"  report to their offering.  , ,     ... The analysts forecast the global multimodal biometrics market ... the period 2016-2020.  Multimodal biometrics is ... as the healthcare, BFSI, transportation, automotive, and government ...
(Date:4/13/2016)...  IMPOWER physicians supporting Medicaid patients in ... standard in telehealth thanks to a new partnership with ... IMPOWER patients can routinely track key health measurements, such ... and, when they opt in, share them with IMPOWER ... local retail location at no cost. By leveraging this ...
Breaking Biology News(10 mins):